Literature DB >> 3791306

Combining interferon with cytotoxic chemotherapy in patients with advanced breast cancer.

R Ashford, T Priestman, T Mott, J M Bottomley.   

Abstract

Laboratory studies have suggested therapeutic synergy between alpha-interferons and various cytotoxic agents. The present study set out to monitor the toxicity of giving a standard cytotoxic drug regimen with a well evaluated, low-dose, schedule of lymphoblastoid interferon. The combined treatment resulted in significantly greater leucopenia than was seen with cytotoxics alone and two patients developed severe infections. Although total numbers were small there was no evidence of increased therapeutic response in the combined treatment group. We would therefore suggest caution in future studies combining cytotoxic drugs and interferons as dose reductions of one or other modality is probably necessary.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3791306     DOI: 10.1007/bf00205653

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  11 in total

1.  Brief communication: Cure of murine leukemia with drug and interferon treatment.

Authors:  M A Chirigos; J W Pearson
Journal:  J Natl Cancer Inst       Date:  1973-10       Impact factor: 13.506

2.  Interferon and cancer.

Authors:  K Sikora; H Smedley
Journal:  Br Med J (Clin Res Ed)       Date:  1983-03-05

3.  Short-course cyclical chemotherapy in advanced breast cancer.

Authors:  G A Edelstyn; T Bates; D Brinkley; K D MacRae; M F Spittle; T Wheeler
Journal:  Lancet       Date:  1977-03-12       Impact factor: 79.321

4.  Efficacy of combined interferon cyclophosphamide therapy after diagnosis of lymphoma in AKR mice.

Authors:  I Gresser; C Maury; M Tovey
Journal:  Eur J Cancer       Date:  1978-01       Impact factor: 9.162

5.  Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial.

Authors:  E C Borden; J F Holland; T L Dao; J U Gutterman; L Wiener; Y C Chang; J Patel
Journal:  Ann Intern Med       Date:  1982-07       Impact factor: 25.391

6.  Effects of interferon on C1300 mouse neuroblastoma.

Authors:  M Tozawa; T Kidowaki; T Tanaka; T Sawada; T Kusunoki; T Oku; T Kishida
Journal:  Cancer Treat Rep       Date:  1982-07

7.  Initial evaluation of human lymphoblastoid interferon in patients with advanced malignant disease.

Authors:  T J Priestman
Journal:  Lancet       Date:  1980-07-19       Impact factor: 79.321

8.  Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay.

Authors:  M S Aapro; D S Alberts; S E Salmon
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

9.  The present status of clinical studies with interferons in cancer in Britain.

Authors:  T J Priestman
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1982-09-24       Impact factor: 6.237

10.  Leukocyte interferon as a possible biological response modifier in lymphoproliferative disorders resistant to standard therapy.

Authors:  R H Clark; N V Dimitrov; J A Axelson; L J Charamella
Journal:  J Biol Response Mod       Date:  1984-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.